ライフサイエンスコーパス: biologics

1 t drug modalities (i.e., small molecules and biologics).

2 vel therapeutics (183 pharmaceuticals and 39 biologics).

3 d thus often offer important advantages over biologics.

4 l and quality of life and may be modified by biologics.

5 7 as examples of targeting ion channels with biologics.

6 lack of exposure to or poor understanding of biologics.

7 e similar in patients who received different biologics.

8 lications for the selection of cell-specific biologics.

9 ed the need for effective IL-33-neutralizing biologics.

10 sociated positive words with self-injectable biologics.

11 strategy in the clinical translation of lead biologics.

12 uch delivery of peptides, proteins and other biologics.

13 ssion after arthroplasty were similar across biologics.

14 a growing trend to target ion channels with biologics.

15 conduct a continuous size-based analysis of biologics.

16 ically modified bacteria for the delivery of biologics.

17 etween IBD patients treated with and without biologics.

18 capabilities compared to small molecules and biologics.

19 strategy is compatible with a wide array of biologics.

20 rsification studies with small molecules and biologics.

21 , and no previous use of immunomodulators or biologics.

22 vention trials with specific agents, such as biologics.

23 to select patients for treatment with type 2 biologics.

24 r new strategies to generate next-generation biologics.

25 n underlying the efficacy of these and other biologics.

26 ely to respond to inhaled corticosteroids or biologics.

27 ts may also benefit from anti-IL-17-targeted biologics.

28 ties suited to the design of multifunctional biologics.

29 cells are the main workhorses for producing biologics.

30 de Onderzoekacties of KU Leuven; and Janssen Biologics.

31 e total psoriasis sample, of whom 37.2% used biologics.

32 o COVID-19 in severe asthmatics treated with biologics.

33 r prescribing of generic drugs and follow-on biologics.

34 gical approaches, surgical determinants, and biologics.

35 ssays to predict cytokine storm responses to biologics.

36 ill unmet needs in improving the delivery of biologics.

37 ue would allow for rapid generation of novel biologics.

38 l small molecule chemotherapeutic agents and biologics.

39 o pharmaceutical manufacturers for drugs and biologics.

40 lar triamcinolone and participants receiving biologics.

41 ficiency for hydrophilic small molecules and biologics.

42 from small molecules and peptidomimetics to biologics.

43 erging as a valuable tool in the analysis of biologics.

44 c arthritis who were naive to treatment with biologics.

45 ation and thus therapeutic efficacy of these biologics.

46 nt differences were found between classes of biologics.

47 tical requirements during the development of biologics.

48 cations of glycoproteins in many therapeutic biologics.

49 Among 9911 patients treated with biologics, 10 923 surgical procedures were identified.

50 rugs (1984-2018), generic drugs (1970-2018), biologics (1984-2018), and vaccines (1998-2018); special

51 Continuous production of biologics, a growing trend in the biopharmaceutical indu

52 Chief among them is how to deliver large biologics across the highly restrictive blood-brain barr

53 Small-molecular entities and biologics acting on various stemness signaling pathways,

54 f stem cell-derived cardiomyocytes and other biologics all necessitate high-throughput (HT), cellular

55 New, fast-acting T2-targeting biologics (already used for preventing asthma exacerbati

56 Participants treated with biologics also had a 2-point or greater decrease (improv

57 ve healing of these tissues that incorporate biologics and are biologic-free are reviewed.

58 y stage of the development and production of biologics and bio-therapeutic formulations.

59 The growing importance of biologics and biosimilars as therapeutic and diagnostic

60 acilitate the development of both originator biologics and biosimilars.

61 nfliximab (IFX) with patients not exposed to biologics and calculated standardized incidence ratios (

62 ), with a shift toward advertising high-cost biologics and cancer immunotherapies.

63 ntial alternative method for the delivery of biologics and engineering MSCs.

64 Two trends related to drugs/biologics and generic drugs/biosimilars underlie this ov

65 soriasis and its treatments, with a focus on biologics and identification of factors associated with

66 at age 60 years or older with a lower use of biologics and immunomodulators but higher absolute risk

67 adult-onset IBD, elderly patients used fewer biologics and immunomodulators but more systemic cortico

68 e treatments, though a consensus agreed that biologics and intravenous immunoglobulin were considered

69 rugs offer future alternatives to the use of biologics and less costly long-term disease management.

70 tient characteristics were found between the biologics and nonmethotrexate/nonbiologics cohorts (eg,

71 thma for more than a decade, three anti-IL-5 biologics and one anti-IL-4R biologic have recently emer

72 is treatment by comparing the perceptions of biologics and other psoriasis therapies between white an

73 e the potential to broaden patient access to biologics and provide cost savings for health care syste

74 s monotherapy or as combination therapy with biologics and safety considerations.

75 ation of different biologics, or mixtures of biologics and small molecule therapeutics.

76 of new therapeutic options with a number of biologics and small molecules targeting potential key me

77 The development of effective biologics and small-molecule kinase inhibitors in the pa

78 gnaling and growth using small molecules and biologics and to facilitate the discovery of drug-respon

79 tempt to give a bird's-eye view of the major biologics and to highlight insights and implications der

80 libraries as a robust method to discover new biologics and uncover membrane-to-nucleus signaling path

81 e framework for development of effective CMV biologics and vaccine design strategies.

82 arative efficacy of top-down (upfront use of biologics and/or immunomodulator therapy) vs step-up the

83 for equitable access to medicines (including biologics) and medical devices; 3.

84 he most commonly investigated modality, GTR, biologics, and combination therapies have also been show

85 er agents including small molecule drugs and biologics, and discuss the challenges and future perspec

86 linical trials for cytomegalovirus vaccines, biologics, and drugs.

87 erstood, and treatment with corticosteroids, biologics, and surgical intervention are the usual thera

88 nation with cytotoxic chemotherapy regimens, biologics, and/or radiotherapy.

89 rier, bone replacement graft with or without biologics) appears to offer an advantage over monotherap

90 Drugs and biologics approved by the FDA that mention TPPs are asso

91 esearch and is being used to produce several biologics approved for use in human or veterinary medici

92 ng to their clinical and commercial success, biologics are a rapidly growing class and have become a

93 Combination drugs are biologics are also discussed.

94 Several biologics are currently available that target proinflamm

95 However, biologics are emerging as important therapeutic tools th

96 Novel therapies such as type 2 targeting biologics are emerging treatment options for patients wi

97 Most peptides and biologics are fused with cationic uptake moieties or for

98 Biologics are made of protein components, and thus can b

99 Moreover, effects of other biologics are now understood to in part be mediated by e

100 he drug development pipeline as many branded biologics are reaching the end of their market exclusivi

101 In parallel, biologics are revolutionizing severe asthma management,

102 and triplets (FOLFOXIRI) in combination with biologics are standard regimens, and efforts are ongoing

103 Although most of these biologics are tested and approved for one or a few indic

104 As new therapeutics (e.g., biologics) are being developed, there is an accompanying

105 Biologic agents (also termed biologicals or biologics) are therapeutics that are synthesized by livi

106 pharmaceutical products, or brand drugs and biologics, are at levels that some assessments consider

107 Biologically derived therapeutics, or biologics, are the most rapidly growing segment of the p

108 peptides are establishing their place in the biologics arm of drug discovery.

109 al Psoriasis Foundation guidelines recommend biologics as an option for first-line treatment of moder

110 critical for the manufacture of high-quality biologics as it enables continuous, real-time and on-lin

111 e with portable or distributed production of biologics, as they typically require the development of

112 notypes that maintain infectivity.IMPORTANCE Biologics based on recombinant AAVs (rAAVs) are increasi

113 lysis was performed on 241 patients naive to biologics before initial ileocolectomy to assess the eff

114 Co-administration of biologics blocking PD-1 and promoting OX40 signaling ind

115 Alternatively, biologics blocking TSLP, IL-33, IL-4 and IL-13, or IgE m

116 acy of immunostimulatory small molecules and biologics by altering their co-localization, biodistribu

117 tent beyond which the viability of preserved biologics can be greatly compromised.

118 advancement and a definitive system by which biologics can be tested and paves the way for personaliz

119 F dual dAb, in comparison to other anti-VEGF biologics, can be explained by increased binding stoichi

120 ple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, a

121 ce area and a more favorable environment for biologics compared to other delivery routes.

122 , which is compatible with diverse drugs and biologics, could enable a broad range of non-cutaneous a

123 nt of allergic and respiratory disorders and biologics currently in development or recently abandoned

124 is interaction have stimulated production of biologics designed to disrupt this essential RNA-protein

125 lipidation can overcome common challenges in biologics development as well as highlight gaps in our u

126 with type 2 inflammation, repeated trials of biologics directed toward type 2 cytokine pathways saw n

127 Administration of TNF-neutralizing biologics disrupted the control of mycobacterial infecti

128 to provide symptomatic control, the current biologics do not prevent the fusion of joints in AS pati

129 d direct visualization and quantification of biologics drug binding in targeted tissues with cellular

130 eliver chemical drugs without excipients and biologics drugs in the presence of sugar excipients into

131 orona, and the ability to easily encapsulate biologics during particle preparation using a mild solve

132 re seen in the comparisons between the newer biologics (e.g. vedolizumab) and the anti-tumor necrosis

133 e in vivo As recently attained for other AAV biologics, e.g., Luxturna and Zolgensma, based on AAV2 a

134 od safety profiles, immunomodulatory agents, biologics (eg monoclonal antibodies), nutritional produc

135 1) Biologics (enamel matrix derivative and recombinant huma

136 umours and lymphoid organs, to alter the way biologics engage with target immune cells and to accumul

137 hese reagents are supplied by the Center for Biologics Evaluation and Research (CBER) or the National

138 mmunogenicity was performed using Center for Biologics Evaluation and Research acceptability criteria

139 Bacterial Polysaccharides in the Center for Biologics Evaluation and Research and transferred to the

140 In the United States, the Center for Biologics Evaluation and Research of the US Food and Dru

141 of antigen and adjuvant dose; the Center for Biologics Evaluation Research and Review (CBER) licensur

142 The survival rates of the first course of biologics for 3,523 biologic-naive patients with chronic

143 ADCs) are among the most promising empowered biologics for cancer treatment.

144 ifferently to the 2 most commonly prescribed biologics for psoriasis: adalimumab (anti-TNF-alpha) and

145 de effects of each of the currently approved biologics for severe uncontrolled asthma and discusses p

146 ergy, with an emphasis on future targets for biologics for the treatment of food allergy.

147 the safety and efficacy of B cell-targeting biologics for the treatment of immune-mediated diseases.

148 dies provided outcome analysis on the use of biologics for the treatment of intrabony defects.

149 e, evaluated the effectiveness of the use of biologics for the treatment of intrabony defects.

150 decade has seen the approval of several new biologics for the treatment of severe asthma-targeting s

151 ell 17 pathway-the target of next-generation biologics for treating psoriasis-based on clinical pheno

152 m for rapid and switchable production of two biologics from a single yeast strain as specified by the

153 in-protein interactions and developing novel biologics from the secreted ARS proteins or their parts.

154 Participants who had experience with biologics generally associated positive words with self-

155 The development of biologics has greatly increased the quality of life and

156 ment (including pharmacotherapy, surgery and biologics) has experienced enormous progress based on th

157 B cell-targeting biologics have been trialled with promising results in d

158 Recent efficacy studies of asthma biologics have included highly enriched patient populati

159 Biologics have limited permeability across the intestine

160 Systemically delivered targeted biologics have revolutionized the treatment of moderate-

161 Biologics have transformed management of inflammatory di

162 oclonal antibodies and peptides, among other biologics, have been encapsulated in silk using various

163 atopic eczema, as well as purpose-developed biologics, have been studied in phase II trials in patie

164 ork was to assess the safety and efficacy of biologics (ie, tumor necrosis factor-alpha antagonists a

165 ble and near-single-dose production of these biologics in <24 h with limited infrastructure requireme

166 user fee funding expanded from new drugs and biologics in 1992 to generic and biosimilar drugs in 201

167 as platforms for presenting receptor-binding biologics in a multivalent format that facilitates recep

168 st-utility analyses conducted for the use of biologics in asthma and other atopic diseases, their con

169 The successes and failures of biologics in clinical trials have facilitated our abilit

170 eceptor antagonist, but the utility of other biologics in MAS is not clear.

171 The initiation of postoperative biologics in naive patients was associated with a reduce

172 thod that has been adopted for encapsulating biologics in nanoparticles (40-200nm) at high loadings (

173 hanism of action and the rationale for using biologics in periodontal plastic surgery, as well as the

174 Relative efficacy of biologics in reducing OCS treatment for severe, uncontro

175 up) and studies of treatment response in the Biologics in Rheumatoid Arthritis Genetics and Genomics

176 a state-of-the-art review on the efficacy of biologics in root coverage procedures, including enamel

177 sts can substitute biosimilars for reference biologics in some EU countries, but not in the USA or Ja

178 Dry preservation of biologics in sugar glasses is regarded as a promising al

179 s eligible for extended surgery and possibly biologics in the future.

180 h superior adverse event profiles, including biologics (in particular, anti-tumour necrosis factor (T

181 tistically significantly more frequent among biologics (incidence rate ratio [IRR] = 1.93; 95% CI, 1.

182 These biologics include immunotherapy with novel anti-IgE anti

183 Most newly developed biologics, including monoclonal antibodies, are structur

184 invasive routes for the systemic delivery of biologics, including subcutaneous, transdermal, oral, in

185 ase who were scheduled to begin therapy with biologics (infliximab or adalimumab) were included, with

186 g five psoriasis treatments: self-injectable biologics, infliximab, methotrexate, apremilast, and pho

187 Other biologics inhibit cytokines such as the p40 subunit of t

188 diment to the translation of small bioactive biologics into drugs.

189 Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients wit

190 d order for combining a second modality with biologics is biologic and methotrexate combination, biol

191 mic stability, prediction of poorly-behaving biologics is difficult, and searching for sequences with

192 y modified bacteria as delivery vehicles for biologics is of considerable interest scientifically and

193 Continuous manufacturing of biologics is one of the priorities of the biopharmaceuti

194 h in extending half-lives of a wide range of biologics, it is unclear whether the existing constructs

195 In the era of biologics, laboratory tests have become essential to eva

196 otein-based pharmacokinetic approaches using biologics like vaccines, monoclonal antibodies, and enzy

197 X as the only biologic vs those unexposed to biologics (malignancy: 1.12/1000 patient-years; HLH: 0.5

198 to targeting eosinophils, IL-5 and anti-IL-5 biologics may have a direct role on AEC.

199 ons, such as long-acting bronchodilators and biologics, may be required in moderate and severe asthma

200 Clinical trials assessing how biologics might improve ICU outcomes are direly needed.

201 maceuticals, including inhaled therapies and biologics, might be key to their treatment.

202 flammatory drugs (NSAIDs) (n = 8), and IR to biologics (n = 3).

203 Exposure was to thiopurines (n = 242), biologics (n = 642), or both (n = 227) vs unexposed (n =

204 will be helpful for the testing of specific biologics neutralizing human TNF.

205 Biologics now constitute a significant element of availa

206 t safety events of novel pharmaceuticals and biologics occur when new safety risks are identified aft

207 Our data did not show any adverse impact of biologics on COVID-19 outcome in patients with psoriasis

208 However, the difference in effects of biologics on ECRS has not been elucidated and warrants f

209 ferent immunosuppressive regimens, including biologics, on HBV reactivation (HBVr) among patients wit

210 Biologic agents (also termed biologics or biologicals) are becoming increasingly impo

211 bers have been restricted to the delivery of biologics or hydrophobic small molecules at low drug loa

212 ed, such as the use of virus-like particles, biologics or novel adjuvants.

213 on (PJI) within 1 year after surgery between biologics or with different dosages of glucocorticoids.

214 gic systemic therapy than in those receiving biologics (OR = 0.68; 95% CI = 0.50-0.94).

215 iologic systemic therapy than in those using biologics (OR = 2.84; 95% CI = 1.31-6.18).

216 sts were higher in IBD patients treated with biologics (OR = 3.98, CI: 3.72-4.27, p < 0.001) when com

217 ctive sites using a combination of different biologics, or mixtures of biologics and small molecule t

218 ncluding a precision medicine approach using biologics, oral desensitization, targeted gut microbiome

219 The FDA approved 355 new drugs and biologics over the study period.

220 ase (P = .046) and undergoing treatment with biologics (P = .04).

221 d fewer immunosuppressants drugs used before biologics (P=0.054) in responders (ie, complete or parti

222 Unfamiliarity with biologics, particularly among black, biologic-naive pati

223 y diseases and the high cost associated with biologics, patient selection is crucial in order to impl

224 The use of biologics (peptide and protein based drugs) has increase

225 With the passage of the Biologics Price Competition and Innovation Act of 2009,

226 C) as a PAT tool for monitoring a continuous biologics process and forced degradation studies.

227 onitor the clearance of these lipases during biologics process development.

228 s therapies has led to an increased focus on biologics produced in mammalian cells.

229 nitors two high risk lipases known to impact biologics product quality, Phospholipase B-like 2 protei

230 Peptides and biologics provide unique opportunities to modulate intra

231 Increased availability of new biologics provides targeted immunotherapies and the oppo

232 Biologics, psychiatric therapeutics, and accelerated and

233 idic device for the continuous monitoring of biologics' purity and bioactivity with high sensitivity,

234 le differences between innovator and copycat biologics raise questions regarding product interchangea

235 ional modulation of the immune response with biologics represents one of the most promising and activ

236 Search terms included "biologics", "rheumatoid arthritis" and their synonyms.

237 Other biologics similarly inhibit TH2 cytokines (thymic stroma

238 le and demand-based production of functional biologics starting from DNA sequence information.

239 review covers the recent small molecule and biologics strategies to target the small GTPases through

240 Type 2-targeting biologics such as anti-IgE, anti-IL4Ralpha, anti-IL5, an

241 In all three examples, biologics such as dupilumab or omalizumab become reliabl

242 Biologics such as etanercept are the most successful dru

243 orm of small-molecule epigenetic modulators, biologics (such as monoclonal antibodies for ET(B)) and

244 Combining biologics, such as etanercept or adalimumab, with photot

245 impurities in recombinantly produced protein biologics, such as host cell proteins (HCP), can potenti

246 The clinical application of biologics supports improvements in clinical parameters c

247 d therapeutic response to corticosteroids or biologics targeting eosinophils.

248 mune diseases, particularly psoriasis, where biologics targeting IL-23 and IL-17 have shown significa

249 currently approved biologic agents, several biologics targeting upstream inflammatory mediators are

250 Biologics targeting vascular endothelial growth factor (

251 The observation that therapeutic biologics, targeting type 2 immune responses, can revers

252 emical entity (NCE) antibacterial drugs, ten biologics, ten NCEs against Mycobacterium tuberculosis,

253 (LIS) had 70% lower odds of having received biologics than those with LIS (odds ratio 0.30; 95% conf

254 Enhancement Agents (VEAs) are a new class of biologics that are designed to increase the uptake of ca

255 e useful for understanding the mechanisms of biologics that are used in patients.

256 represents a prototype for structure-guided biologics that can efficiently repair or remodel neurona

257 ts toward development of small molecules and biologics that could be of therapeutic use.

258 ven models and compared with other anti-VEGF biologics that have been used in ocular anti-angiogenic

259 Biologics that inhibit TNF-alpha, p40IL-12/23, and IL-17

260 moderate to severe plaque psoriasis include biologics that inhibit TNF-alpha, p40IL-12/23, IL-17, an

261 Treg biology so as to develop pharmacologics/biologics that modulate Treg for asthma therapy.

262 Biologics that neutralize specific cytokines have improv

263 isease is improved by treatment with current biologics that target disease-specific pathways is uncle

264 is therefore growing interest in developing biologics that target TSLP, IL-33, and IL-25.

265 In patients naive to preoperative biologics, the initiation of postoperative biologics was

266 </=90 kg or >90 kg) and previous exposure to biologics therapy for psoriasis.

267 proval process and market launches for these biologics, therefore expanding patient access to these p

268 pregnancies exposed vs unexposed in utero to biologics, thiopurines, or a combination.

269 ring, and the real-time quality assurance of biologics throughout the biomanufacturing processes.

270 Although most of the successful biologics to date are drugs that bear a peptidic backbon

271 that it is possible to discriminate between biologics to inform clinical practice and decision makin

272 (AF) repair strategy that delivers cells and biologics to IVD injury site is needed to limit the prog

273 re biomarkers that enhance the usefulness of biologics to manage uncontrolled asthma, urticaria, and

274 However, delivering large biologics to primary T lymphocytes directly in vivo is t

275 e stimulants and immune checkpoint inhibitor biologics to produce durable cures in mouse models of gl

276 oengineered glands, and development of drugs/biologics to stimulate in vivo regeneration or increase

277 apies, leading to the development of several biologics to treat allergic diseases.

278 Despite the introduction of biologics, topical dithranol (anthralin) has remained on

279 he US Food and Drug Administration regulates biologics used for diagnosis and treatment of allergic d

280 udesonide effervescent tablet in Europe; (2) biologics used for other T(H)2-mediated diseases, such a

281 assessed the risk of serious infections for biologics used to treat psoriasis by comparison with a c

282 We assessed the drug survival of biologics used to treat psoriasis in a prospective natio

283 fluorescent labeling of target proteins and biologics using click chemistries, (ii) for glycoenginee

284 n small airway narrowing of type-2 targeting biologics using pooled data from two similarly design ra

285 e biologics, the initiation of postoperative biologics was associated with a 40% decreased incidence

286 nual number of new drug approvals, including biologics, was 34 from 1990-1999, 25 from 2000-2009, and

287 btle differences in vibrational modes of the biologics, we have developed partial least-squares-discr

288 With the renewed interest in anti-TH2 biologics, we propose a rationale for why they are parti

289 Similarly, the odds of having received biologics were 69% lower among black patients compared w

290 A number of different drugs or biologics were critically reviewed and 3 different poste

291 the total costs in IBD patients treated with biologics were due to drug costs, compared with 28% in p

292 All included biologics were efficacious compared with placebo or meth

293 The biologics were supplemented with an initial 1-month trea

294 Biologics, which target specific cytokines and pathways,

295 e are overall insufficient data on combining biologics with acitretin, cyclosporine, or a second biol

296 okine-receptor targeting small molecules and biologics with novel pharmacology.

297 ntify direct and indirect evidence comparing biologics with one another, methotrexate, or placebo.

298 18, 2013, that evaluated therapies combining biologics with phototherapy, oral medications, or other

299 tial strategy of etanercept-methotrexate and biologics with similar cost and efficacy is unlikely to

300 c scaffolds are more appropriate for smaller biologics without secondary structure.